Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Research

Pneumonia-Specific Escherichia coli with Distinct Phylogenetic and Virulence Profiles, France, 2012–2014

Béatrice La Combe, Olivier Clermont, Jonathan Messika, Matthieu Eveillard, Achille Kouatchet, Sigismond Lasocki, Stéphane Corvec, Karim Lakhal, Typhaine Billard-Pomares, Romain Fernandes, Laurence Armand-Lefevre, Sandra Bourdon, Jean Reignier, Vincent Fihman, Nicolas de Prost, Julien Bador, Julien Goret, Frederic Wallet, Erick Denamur, Jean-Damien RicardComments to Author , on behalf of the COLOCOLI group
Author affiliations: Infection, Antimicrobiens, Modélisation, Évolution, Paris, France (B. La Combe, O. Clermont, J. Messika, T. Billard-Pomares, R. Fernandes, L. Armand-Lefevre, E. Denamur, J.-D. Ricard); Université Paris Diderot, Paris (B. La Combe, O. Clermont, J. Messika, T. Billard-Pomares, R. Fernandes, L. Armand-Lefevre, E. Denamur, J.-D. Ricard); Hôpital Louis Mourier, Colombes, France (B. La Combe, J. Messika, T. Billard-Pomares, R. Fernandes, J.-D. Ricard); Centre Hospitalier Universitaire, Angers, France (M. Eveillard, A. Kouatchet, S. Lasocki); Centre Hospitalier Universitaire, Nantes, France (S. Corvec, J. Reignier); Hôpital Laënnec, Nantes (K. Lakhal); Hôpital Bichat, AP-HP, Paris (L. Armand-Lefevre, E. Denamur); Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France (S. Bourdon); Hôpital Henri Mondor, AP-HP, Créteil, France (V. Fihman, N. de Prost); Centre Hospitalier Universitaire Bocage Central, Dijon, France (J. Bador); Centre Hospitalier Universitaire Pellegrin, Bordeaux, France (J. Goret); Centre Hospitalier Régional Universitaire, Lille, France (F. Wallet)

Main Article

Table 3

Demographics and clinical characteristics of 243 pneumonia patients requiring mechanical ventilation, from whom Escherichia coli was isolated, France, 2012–2014*

Characteristic Value
Age, y, median (IQR)
 64 (52–73)
Sex
M 183 (75.3)
F
 60 (24.7)
SAPS II at admission, median (IQR)
 57 (42–69)
Comorbid conditions
Chronic alcohol consumption 56 (23)
Diabetes mellitus 45 (18.5)
Neoplasic disease 43 (17.7)
Immunosuppression† 77 (31.7)
Cirrhosis 12 (4.9)
Chronic kidney disease 18 (7.4)
Dialysis 5 (2.1)
Chronic respiratory disease 33 (13.6)
Chronic heart failure
 43 (17.7)
Reason for ICU admission
Acute respiratory failure 61 (25.1)
Coma 48 (19.8)
Septic shock 44 (18.1)
Cardiac arrest 28 (11.5)
Cardiogenic shock 14 (5.8)
Polytrauma 22 (9.1)
Postoperative care 8 (3.3)
Hemorrhagic shock
 5 (2.1)
Exposure to antimicrobial drug therapy in previous 3 mo 98 (40.3)
Amoxicillin 6 (2.5)
Amoxicillin/clavulanic acid 38 (15.6)
Third-generation cephalosporin 19 (7.8)
Aminoglycosides 29 (11.9)
Piperacillin/tazobactam 24 (9.9)
Quinolone 10 (4.1)
Carbapenem
 11 (4.5)
Polymicrobial sampling 57 (23.5)
ICU length of stay, d (IQR) 17 (7–33)
Hospital length of stay, d (IQR)
 24 (10–45)
Death
While in ICU 90 (37)
While in hospital 99 (40.7)
Associated with E. coli 27 (11.1)

*Values are no. (%) except as indicated. ICU, intensive care unit; IQR, interquartile range; SAPS II, Simplified Acute Physiology Score II.
†Defined by >1 immunosuppression factor among neoplastic disease, hematologic malignancy, HIV infection, immunosuppressive therapy, corticosteroids therapy.

Main Article

1Group members are listed at the end of this article.

Page created: March 04, 2019
Page updated: March 04, 2019
Page reviewed: March 04, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external